Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178345 · ClinicalTrials.gov registry record
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 123
- Enrollment target
NCT02178345: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02178345 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 123 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02178345 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 123 participants
- Enrollment target
Study Summary
Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt. Perfusion MRI uses faster imaging. It also includes a contrast material that is given by vein. This makes specific organs, blood vessels, or tumors easier to see. Diffusion MRI lets us measure the motion of water in the tumor. Perfusion and diffusion MRI give extra information which is not available with the regular MRI. A regular MRI only shows pictures of the tumor. Thyroid MRI scans are not part of the current standard of care. The purpose of this study is to see if new MRI methods can give us more information about the tumor.
Interventions
- PROCEDURE diffusion weighted (DW) MRI
- PROCEDURE dynamic contrast agent (DCE) MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2014-06-24 |
| Est. Completion | 2021-12-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02178345
The ClinicalTrials.gov registry entry for NCT02178345 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which diffusion weighted (DW) MRI is the first listed.
NCT02178345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02178345 about?
NCT02178345 is a clinical study titled "Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer". Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt. Perfusion MRI uses faster imaging. It also includes a contrast material that is given by vein. This makes specific organs, blood vessels,...
What is the current status of trial NCT02178345?
This trial is currently completed. The enrollment target is 123 participants. The study started on 2014-06-24. Estimated completion is 2021-12-03.
What interventions are being tested in trial NCT02178345?
The interventions under investigation include: diffusion weighted (DW) MRI (PROCEDURE), dynamic contrast agent (DCE) MRI (PROCEDURE).
Who is sponsoring clinical trial NCT02178345?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.